Стволовые клетки- производные вирусные Ag-специфические T Лимфоциты подавить HBV репликации у мышей

Overview

This article presents a protocol for the suppression of hepatitis B virus (HBV) replication in mice using adoptive cell transfer (ACT) of stem cell-derived viral antigen-specific T lymphocytes. The method emphasizes the use of iPSC-derived T cells with a naive phenotype and a single type T cell receptor.

Key Study Components

Area of Science

• Immunology
• Virology
• Cellular Therapy

Background

• Hepatitis B virus (HBV) is a significant global health issue.
• Adoptive cell transfer (ACT) is a promising therapeutic approach.
• iPSC-derived T cells offer advantages in specificity and phenotype.
• Understanding T cell differentiation is crucial for effective therapy.

Purpose of Study

• To develop a protocol for HBV suppression in a mouse model.
• To utilize iPSC-derived T cells for targeted therapy.
• To assess the effectiveness of ACT in viral replication control.

Methods Used

• Transduction of iPSCs with HBV-specific T cell receptor genes.
• Co-culture of transduced iPSCs on OP9-DL1/DL4 monolayers.
• Monitoring cell morphology during differentiation.
• Harvesting and centrifugation of differentiated T cells.

Main Results

• Successful differentiation of HBV-specific CD8-positive T cells.
• Demonstrated potential for ACT in suppressing HBV replication.
• Characterization of T cell responses in the mouse model.
• Insights into the efficacy of iPSC-derived T cells in therapy.

Conclusions

• The protocol provides a foundation for ACT-based immunotherapy.
• iPSC-derived T cells show promise in targeting HBV.
• Further studies are needed to optimize therapeutic applications.

Frequently Asked Questions